1Andrew R, Gale CR, Walker BR, et al. Glucocorticoid metabolisnl and the metabolic syndrome: associations in an elderly cohort. Exp Clin Endocrinol Diabetes,2002,110:284-290.
2Faggiano A,Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliher and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endoerinol Metab ,2003,88:2527-2533.
3Gabriely I Ma XH,Yang XM,et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes,2002,51:2951-2958.
4Lindsay RS, Wake D J, Nair S, et al. Subcutaneous adipose 11 beta- hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab, 2003,88: 2738-2744.
5Tomlinson JM, Draper N, Maekie J,et al. Absence of cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to eortisol conversion. J Clin Endoerinol Metab,2002,87:57-62.
6Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolie syndrome and prevents progression of atheroselerosis in mice. J Exp Med ,2005,202:517-527.
7Alberts P,Nilsson C, Selen G. Selective inhibition of 11 beta-hydroxvsteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology ,2003,144:4755-4762.
8Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocovticolds and risk of cardiovascular and eerebrovaseular disease in a population based case-control study. Heart,2004,90:859-865.
9Wei L, MacDonald TM, Walker BR. Taking glucoeorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med,2004,141:764-770.
10Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis,2003,62:1071-1077.
